Skip to main content

BioCommerce Week s Index to the Diversified Molecular Biology Tools Companies: Dec 23, 2004


Bruker and Sigma Only Gainers as BCW Index Falls

Bruker shares ended a two-week slide this week with a 2.6-percent gain, while Sigma-Aldrich inched up 0.7 percent as the only two gainers among the 15 multiplatform molecular biology tools companies whose share prices are tracked weekly on the BioCommerce Week Index.

Bruker BioSciences closed the five-day tracking period Tuesday at $4.29, compared to last week’s $4.18 after announcing on Monday a $3-million second phase of a cost-cutting initiative originally announced in September (see story, page 9). Bruker shares have closed up on four of the last six weeks.

Sigma’s stock was up for the second week in a row, closing at $60.89, up over last week’s $60.46.

Harvard Bio shares led 13 losers on the week with a 2.7 percent drop, closing at $4.35 for the week after last week’s close of $4.47.

PerkinElmer dropped 2.6 percent even after affirming analysts’ expectations for FY ‘05 in its guidance conference call on Friday (see story, page 1). The company’s shares closed at $22.10, down from last week’s $22.70.

Investors responded to Invitrogen’s strategic alliance with Illumina (see story, page 1) with a 2.5 percent drop, as IVGN closed at $65.95, down from $67.63 last week.

Beckman Coulter, Bio-Rad, Waters, Applied Biosystems, Agilent, and Molecular Devices all saw share-price drops of over 1 percent. Beckman and Bio-Rad fell 1.9 percent; Waters was down 1.7 percent; Applied Biosystems and Agilent fell 1.6 percent; and Molecular Devices was off 1.3 percent as acquired Axon co-founder Alan Finkel and his wife Elizabeth sold 500,000 shares for $10.7 million.

BD, GE, Thermo, and Stratagene shares all dropped fractions of a percent.

Overall, the index closed at $34.39 for the week, dropping 1.3 percent from last week’s close of $35.40 on a day when all of the major indices closed at 52-week highs. The BCW Index has finished up for seven out of the last nine weeks.

— Mo Krochmal ([email protected])

File Attachments
The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.